Cargando…

Kernel learning for ligand-based virtual screening: discovery of a new PPARγ agonist

Detalles Bibliográficos
Autores principales:	Rupp, Matthias, Schroeter, T, Steri, R, Proschak, Ewgenij, Hansen, K, Zettl, H, Rau, O, Schubert-Zsilavecz, M, Müller, K-R, Schneider, Gisbert
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2010
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2867160/ http://dx.doi.org/10.1186/1758-2946-2-S1-P27

Ejemplares similares

Urate transporter inhibitor lesinurad is a selective peroxisome proliferator-activated receptor gamma modulator (sPPARγM) in vitro
por: Heitel, Pascal, et al.
Publicado: (2018)

PocketPicker: analysis of ligand binding-sites with shape descriptors
por: Weisel, Martin, et al.
Publicado: (2007)

Structure-Based Virtual Screening and Discovery of New PPARδ/γ Dual Agonist and PPARδ and γ Agonists
por: Maltarollo, Vinicius G., et al.
Publicado: (2015)

Heterodimer formation with retinoic acid receptor RXRα modulates coactivator recruitment by peroxisome proliferator-activated receptor PPARγ
por: Kilu, Whitney, et al.
Publicado: (2021)

DOGS: Reaction-Driven de novo Design of Bioactive Compounds
por: Hartenfeller, Markus, et al.
Publicado: (2012)

SBE13, a newly identified inhibitor of inactive polo-like kinase 1
por: Keppner, Sarah, et al.
Publicado: (2010)

Microglia and Astrocyte Activation by Toll-Like Receptor Ligands: Modulation by PPAR-γ Agonists
por: Gurley, Catherine, et al.
Publicado: (2008)

Allosteric modulation of the farnesoid X receptor by a small molecule
por: Gabler, Matthias, et al.
Publicado: (2018)

Targeting the Alternative Vitamin E Metabolite Binding Site Enables Noncanonical PPARγ Modulation
por: Arifi, Silvia, et al.
Publicado: (2023)

Zafirlukast Is a Dual Modulator of Human Soluble Epoxide Hydrolase and Peroxisome Proliferator-Activated Receptor γ
por: Göbel, Tamara, et al.
Publicado: (2019)

Nutraceuticals as Ligands of PPARγ
por: Penumetcha, Meera, et al.
Publicado: (2012)

Expression of peroxisome proliferator-activated receptor (PPAR)γ in gastric cancer and inhibitory effects of PPARγ agonists
por: Sato, H, et al.
Publicado: (2000)

In silico polypharmacology: retrospective recognition vs. rational design
por: Proschak, Ewgenij
Publicado: (2014)

Structural Basis for PPARs Activation by The Dual PPARα/γ Agonist Sanguinarine: A Unique Mode of Ligand Recognition
por: Tian, Siyu, et al.
Publicado: (2021)

Emerging PPARγ-Independent Role of PPARγ Ligands in Lung Diseases
por: Kulkarni, Ajit A., et al.
Publicado: (2012)

PPARγ Agonists: Blood Pressure and Edema
por: Blazer-Yost, Bonnie L.
Publicado: (2010)

PPARγ Agonists: Emergent Therapy in Endometriosis
por: Vallée, Alexandre, et al.
Publicado: (2021)

Activity Screening of Fatty Acid Mimetic Drugs Identified Nuclear Receptor Agonists
por: Helmstädter, Moritz, et al.
Publicado: (2022)

Effects of PPARγ Ligands on Leukemia
por: Tabe, Yoko, et al.
Publicado: (2012)

Gastrointestinal Cytoprotection by PPARγ Ligands
por: Naito, Yuji, et al.
Publicado: (2010)

Scaffold Hopping from Amodiaquine to Novel Nurr1 Agonist Chemotypes via Microscale Analogue Libraries
por: Willems, Sabine, et al.
Publicado: (2022)

An alternate binding site for PPARγ ligands
por: Hughes, Travis S., et al.
Publicado: (2014)

Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)α agonist fenofibrate and the PPARγ agonist pioglitazone
por: Syversen, Unni, et al.
Publicado: (2009)

Scaffold-Based Pan-Agonist Design for the PPARα, PPARβ and PPARγ Receptors
por: Zhang, Li-Song, et al.
Publicado: (2012)

Comparative Gene Expression Profiles Induced by PPARγ and PPARα/γ Agonists in Human Hepatocytes
por: Rogue, Alexandra, et al.
Publicado: (2011)

PPARγ Agonists: Potential as Therapeutics for Neovascular Retinopathies
por: Pershadsingh, Harrihar A., et al.
Publicado: (2008)

The Role of PPARγ in the Transcriptional Control by Agonists and Antagonists
por: Tsukahara, Tamotsu
Publicado: (2012)

PPARγ Agonist Beyond Glucose Lowering Effect
por: Sugawara, Akira, et al.
Publicado: (2011)

Relaxation of human pulmonary arteries by PPARγ agonists
por: Kozłowska, Hanna, et al.
Publicado: (2013)

Biological Rationale for the Use of PPARγ Agonists in Glioblastoma
por: Ellis, Hayley Patricia, et al.
Publicado: (2014)

PPAR-γ Agonists and Their Role in Primary Cicatricial Alopecia
por: Harnchoowong, Sarawin, et al.
Publicado: (2017)

PPARγ and Its Agonists in Chronic Kidney Disease
por: Ma, Yuhua, et al.
Publicado: (2020)

Anti-Diabetic Actions of a Non-Agonist PPARγ Ligand Blocking Cdk5-Mediated Phosphorylation
por: Choi, Jang Hyun, et al.
Publicado: (2011)

Clinical Use of PPARγ Ligands in Cancer
por: Hatton, Jennifer L., et al.
Publicado: (2008)

PPAR-γ Thiazolidinedione Agonists and Immunotherapy in the Treatment of Brain Tumors
por: Lichtor, Terry, et al.
Publicado: (2008)

New Insights into the PPARγ Agonists for the Treatment of Diabetic Nephropathy
por: Jia, Zhanjun, et al.
Publicado: (2014)

Therapeutic potential of PPARγ natural agonists in liver diseases
por: Wu, Liwei, et al.
Publicado: (2020)

Dual PPAR α/γ Agonists: Continuing Cardiac Concerns
por: Balachandran, Karthik
Publicado: (2019)

Obesity-linked phosphorylation of PPARγ by cdk5 is a direct target of the anti-diabetic PPARγ ligands
por: Choi, Jang Hyun, et al.
Publicado: (2010)

Synthesis of Phthalimide Derivatives as Potential PPAR-γ Ligands
por: Eom, So Hyeon, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_00gcb20r6o4sgalkhqatuk4oq5